MENU
SUPN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

SUPN stock forecast, quote, news & analysis

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company... Show more

SUPN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SUPN with price predictions
Jul 02, 2026

SUPN's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for SUPN turned positive on June 18, 2026. Looking at past instances where SUPN's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SUPN's RSI Oscillator exited the oversold zone, of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on June 26, 2026. You may want to consider a long position or call options on SUPN as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

SUPN moved above its 50-day moving average on July 01, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in of 323 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 50-day moving average for SUPN moved below the 200-day moving average on June 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SUPN broke above its upper Bollinger Band on June 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SUPN entered a downward trend on June 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SUPN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.398) is normal, around the industry mean (79.618). P/E Ratio (49.565) is within average values for comparable stocks, (97.708). SUPN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.629). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (3.257) is also within normal values, averaging (95.237).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.11B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 1%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 19%. UPC experienced the highest price growth at 123%, while AKAN experienced the biggest fall at -17%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -37%. For the same stocks of the Industry, the average monthly volume growth was -28% and the average quarterly volume growth was -50%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 66
Price Growth Rating: 56
SMR Rating: 87
Profit Risk Rating: 82
Seasonality Score: 3 (-100 ... +100)
View a ticker or compare two or three
SUPN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer for the treatment of central nervous system

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Pharmaceuticals Other
Address
9715 Key West Avenue
Phone
+1 301 838-2500
Employees
778
Web
https://www.supernus.com
SUPN's MACD Histogram just turned positive